Jan. 16, 2020: Arena Pharmaceuticals, Inc. announced that the U.S. FDA granted Fast Track designation for APD418, a β3-adrenergic receptor (AdrR) antagonist and cardiac myotrope, in development for the treatment of decompensated heart failure (DHF). Around 10 million DHF patient hospital visits expected in the US by 2025 and few viable treatment options.
APD418 has the prospective to make a significant impact for these patients.APD418 is a β3-adrenergic receptor (AdrR) antagonist and cardiac myotrope for the decompensated heart failure (DHF).
APD418 is a selective antagonist designed in order to improve cardiac contractility with minimal effect on heart rate, blood pressure and myocardial oxygen consumption, thus potentially avoiding adverse events associated with current inotrope therapies. Arena discovered and developed this investigational drug aspirant internally. http://invest.arenapharm.com/news-releases/news-release-details/fda-grants-fast-track-designation-arena-pharmaceuticals-apd418
